Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1371260 | Bioorganic & Medicinal Chemistry Letters | 2012 | 4 Pages |
Abstract
Calcium-dependent protein kinase-1 (CDPK1) from Cryptosporidium parvum (CpCDPK1) and Toxoplasma gondii (TgCDPK1) have become attractive targets for discovering selective inhibitors to combat infections caused by these protozoa. We used structure-based design to improve a series of benzoylbenzimidazole-based compounds in terms of solubility, selectivity, and potency against CpCDPK1 and TgCDPK1. The best inhibitors show inhibitory potencies below 50 nM and selectivity well above 200-fold over two human kinases with small gatekeeper residues.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Zhongsheng Zhang, Kayode K. Ojo, Steven M. Johnson, Eric T. Larson, Penqing He, Jennifer A. Geiger, Alejandro Castellanos-Gonzalez, A. Clinton White Jr., Marilyn Parsons, Ethan A. Merritt, Dustin J. Maly, Christophe L.M.J. Verlinde,